Human medicines European public assessment report (EPAR): Ponlimsi, denosumab, Date of authorisation: 17/11/2025, Revision: 1, Status: Authorised

Human medicines European public assessment report (EPAR): Nyvepria, pegfilgrastim, Date of authorisation: 18/11/2020, Revision: 9, Status: Authorised

Human medicines European public assessment report (EPAR): Libtayo, cemiplimab, Date of authorisation: 28/06/2019, Revision: 22, Status: Authorised

Human medicines European public assessment report (EPAR): Imnovid (previously Pomalidomide Celgene), pomalidomide, Date of authorisation: 05/08/2013, Revision: 26, Status: Authorised

Human medicines European public assessment report (EPAR): Hycamtin, topotecan, Date of authorisation: 12/11/1996, Revision: 42, Status: Authorised

PSUSA/00001506/202504

Agenda of the CAT meeting 21-23 January 2026

Committee for Advanced Therapies (CAT): 21-23 January 2026, European Medicines Agency, Amsterdam, the Netherlands, from 21 January 2026 to 23 January 2026

Human medicines European public assessment report (EPAR): Odomzo, sonidegib, Date of authorisation: 14/08/2015, Revision: 11, Status: Authorised

Data access to medicinal products for human use - Chapter 5 Annex A: Product data elements accessible by stakeholder group